The objective of this study was to elucidate the mechanism underlying the further suppression of serum testosterone (T) by diethylstilbestrol diphosphate (DES-DP) in patients with prostate cancer refractory to hormonal treatment.
APPROXIMATELY
one-third of the patients with prostate cancer have clinical metastases when initially diagnosed.
Patients with advanced prostate cancer first undergo medical or surgical castration in order to reduce the serum levels of testosterone (T). Most of these patients show some improvement after testicular androgen ablation [1] . However, almost all patients with an initially good response to such therapy relapse and die within a few years [2] . Their condition is termed hormone-refractory [3] .
The administration of synthetic estrogens may be of benefit in patients with hormone-refractory prostate cancer, although the duration and the benefit are limited [4, 5] . The mechanisms for these beneficial effects were not known until recently, when a direct cytotoxic effect of diethylstilbestrol diphosphate (DES-DP) on prostate cancer cells was reported in vitro [6] . We previously showed that a therapeutic per os dose of DES-DP, a synthetic estrogen, suppresses serum total T to undetectable levels.
The effect is significantly stronger than that of surgical castration or of the administration of an LH-RH agonist [7] . We presume a potent suppressive effect on serum T might be one of the mechanisms of DES-DP action in patients with hormone-refractory prostate cancers.
Such cancer is able to proliferate even at a level of serum T fol-lowing induction of castration, approximately 5% of serum T level before castration.
Adrenal androgens are thought to be the source of serum T following surgical or medical castration. We hypothesized that DES-DP might affect the pathway of steroid biosynthesis or its metabolism. Accordingly, in the present study, we measured serum levels of several hormones including adrenal steroids and sex hormone-binding globulin (SHBG) in patients with hormone refractory prostate cancer, before and during the intravenous administration of large doses of DES-DP in an effort to elucidate the mechanism of suppression of serum T by DES-DP.
Subjects and Methods

Patient characteristics
Profiles of our seven patients are shown in Table 1 . These Japanese men, aged 53 to 93 years, had been diagnosed as having advanced prostate cancer with bone metastasis and had been treated with an LH-RH agonist, gosereline acetate (Zeneca Japan Pharmaceutical Co. Ltd., Tokyo) or leuprorelin acetate (Takeda Pharmaceutical Co. Ltd., Osaka), with or without an anti-androgen (chlormadinone acetate, a synthetic progesterone; Teikoku Hormone Mfg. Co., Ltd., Tokyo) or hydroxyflutamide, a non-steroidal androgen blocker (Nikon Kayaku Co. Ltd., Tokyo). These patients had initially shown an improvement on such treatment but had relapsed 4 to 24 months later. The relapse was confirmed by determination of serum levels of prostatic acid-phosphatase (PAP) or prostatic specific antigen (PSA), computerized tomography (CT) scans, and bone scintigraphy. Most patients were experiencing bone pain related to progressive bone metastases.
Clinical protocol
Each patient received DES-DP (Honvan: Kyorin Pharmaceutical Co. Ltd., Tokyo) at a daily dose of 1000 mg, sometimes reduced to 500 mg, based on body weight and cardiovascular status. DES-DP, 250 mg or 500 mg, was freshly diluted in 250 mL of 5% dextrose and infused for 3 hours twice daily. A dose of 81 mg acetylsalicylic acid was given orally everyday during the treatment to prevent thrombosis.
The patients were weighed daily. Blood samples were collected at 0600-0800 h on day 1 to 2 wk before the beginning of treatment and again on the last day of the treatment, with the patient's informed consent.
Hormone assays Serum and plasma prepared from blood samples were stored frozen at -80°C until assayed. All circulating hormones in serum were measured by radioimmunoassay in this study; i.e., ACTH, LH, FSH, aldosterone, androstenedione, cortisol, 17a-hydroxypregnenolone, 17a-hydroxyprogesterone, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), free and total testosterone (T), and estradiol (E2). Sex hormonebinding globulin (SHBG) was measured by an immunoradiometric assay. The intraassay CV varied from 2.5% in LH to 17% for 17a-hydroxyprogesterone, while the interassay CV varied from 2.1% in LH to 20% for 17a-hydroxyprogesterone.
Statistical analysis
Data are expressed as mean±SD.
The effects of DES-DP were confirmed by the Wilcoxon signedrank (paired) test using Stat View (statistics software from Abacus Concepts, Inc., Berkeley, CA). For convenience in statistical analysis, an undetectable level was considered to be the lower limit of detection. A level of p <0.05 was accepted as statistically significant.
Results
Edema caused one patient to discontinue the treatment on the 14th day, and two patients developed loss of appetite, but were able to continue therapy (Table 1) . In the 7 patients in whom the data were evaluative, no significant difference was observed in circulating levels of the hormones and SHBG measured for the three androgen-deprivation therapy, that is, an LHRH agonist, an LHRH agonist with chlormadinone acetate, or an LHRH agonist with hydroxyflutamide (Tables 1-5 ). Therefore, all three androgen ablation therapies were considered to exert similar effects on the hormonal milieu. (Table 2 ). Serum free T was not detected except for one patient with DES-DP treatment, while no significant change in serum DHT levels was observed with DES-DP treatment (Table 2) . For pituitary hormones, serum FSH decreased significantly (p = 0.042) and both LH and ACTH showed no change during DES-DP administration (Table 3) .
For serum steroids which are thought to be mainly from the adrenal, DES-DP treatment increased cortisol (p = 0.018) and decreased DHEA-S (p = 0.034) approximately one third significantly in comparison with previous androgen ablation therapies (Tables 4,  5 ). Serum levels of 17a-hydroxyprognenolone, 17a-hydroxyprogesterone, DHEA, androstenedione and aldosterone appeared to be unaffected by DES-DP treatment (Table 4 , 5).
Discussion
The endocrine effect of exogenous estrogens on serum T is thought to be due to suppression of the serum level of LH, i.e., acting via a negative feedback mechanism [8, 9] . As we observed in the present study and have previously reported, not only an LH-RH agonist but also therapeutic doses of DES-DP reduce the serum level LH to an undetectable Table   4 .
Serum levels of steroids before and during diethylstilbestrol diphosphate treatment in patients with hormone-refractory prostate cancer level, although serum levels of T are suppressed more strongly by DES-DP than by an LH-RH agonist or by bilateral orchiectomy or by combined androgen blockade with an LH-RH agonist and an androgen receptor blocker [7] . The detectable T in serum of the patients treated by an LH-RH agonist, with or without one of the anti-androgens, or surgical castration must originate from serum adrenal androgens.
The serum level of DHEA-S, a representative circulating adrenal androgen, was decreased to approximately two-thirds of the pretreatment level following the administration of DES-DP. In contrast, the level of serum cortisol was significantly increased, but that of other adrenal steroids was not. Although an elevation of serum ACTH by estrogen has been reported by some investigators [10] , the level of ACTH in the elderly patients in the present study administered anti-androgen therapy was not affected by DES-DP. These observations suggest that DES-DP blocks some pathway of steroid synthesis or metabolism in these patients. We infer that only DHEA-S, among the adrenal androgens measured in the present study, is affected by DES-DP, because most of the adrenal androgens are secreted as DHEA-S. One possible mechanism of the effect on serum DHEA-S is the inhibition of C17_20 lyase activity by DES-DP, which could increase the cortisol level and decrease the level of adrenal androgens. The same effect of estrogen was reported in the murine testis in vitro [11 , 12] . However, an increased clearance of adrenal steroids resulting from a decrease in serum albumin and an effect on liver function have been also postulated as the main cause of the suppression of serum DHEA-S by exogenous estrogens [9, 13] . We conjecture that a bioconversion from adrenal androgens and testosterone involving activity of 3 j3-hydroxysteroid dehydrogenase or 17p-hydroxysteroid dehydrogenase at peripheral sites is also being influenced by DES-DP [8] .
The almost complete ablation of serum free T by DES-DP administration appears to result from both increase of serum SHBG and a strong suppression of serum T. On the other hand, the fact that serum DHT did not show a decrease following the administration of DES-EP, even though serum levels of T, E2 and DHEA-S were all decreased by DES-DP, is hard to explain from the present data. We speculate that bioconversion from adrenal androgens to DHT via androstenediol might have been activated by the administration of DES-DP. The existence of a similar phenomenon has been confirmed in the prostate following castration [8, 14, 15] . We assume that the maximal ablation of serum free T by the administration of high dose DES-DP has some advantage in treating patients with hormone refractory prostate cancer, considering the beneficial effect to the patients who suffer a relapse after androgen ablation treatment and evidence of amplification of androgen receptor genes in hormonerefractory prostate cancer cells [16, 17] . That is, the condition of the disease, at least in some cases, after androgen-deprivation therapy is not completely hormone-independent but remains endocrine-sensitive, probably androgen-hypersensitive. Clinical reports on ketoconazole, a P450 inhibitor, and/or glucocorticoid therapy administered for hormone refractory prostate cancer [18, 19] and in vitro studies of mutant androgen receptor in prostate cancer cells [20] support the progressive effect of adrenal androgens on prostate cancer, especially those that are hormone-refractory.
While the administration of high doses of DES-DP decreases serum T from castration level to undetectable ones in patients receiving androgen ablation therapy, the reduction in serum DHEA-S produced by high doses of DES-DP was only one-third of the serum levels by androgen ablation therapy. These results suggest that a combination therapy of estrogen, glucocorticoid and ketoconazole may be more beneficial to some patients with hormone-refractory prostate cancer than an estrogen therapy when the adverse effects are mild.
In conclusion, the potent suppression of circulating T by high doses of DES-DP appears to result, at least in part, from suppression of serum levels of DHEA-S, a representative adrenal androgen, by DES-DP.
The suppression of serum adrenal androgens and the increase in serum SHBG appeared to produce a maximal decline in serum free T. The mechanism responsible for the unchanged levels of DHT after the administration of DES-DP requires further study. 
